SHORT-TERM TREATMENT WITH UNFRACTIONATED HEPARIN OR ENOXAPARIN AMONG PATIENTS ADMITTED WITH ACUTE MYOCARDIAL INFARCTION IN A TERTIARY CARE CENTRE – A COST MINIMIZATION ANALYSIS
DOI:
https://doi.org/10.22159/ajpcr.2025v18i10.54489Keywords:
Unfractionated heparin, Enoxaparin, Direct medical cost,, Acute myocardial infarction.Abstract
Objective: To estimate the direct medical cost associated with unfractionated heparin (UFH) and enoxaparin among hospitalized patients with acute myocardial infarction (AMI) in a tertiary care center.
Methods: The present cohort study was conducted among hospitalized patients treated with UFH or Enoxaparin for AMI in a tertiary care center. Costs of the drugs, supplies for administration, and costs of laboratory test monitoring were added to calculate the total medical cost. The researchers assumed other costs were equivalent between the two groups.
Results: Researchers included 100 patients aged 40–88 years, admitted with AMI, with a mean age of 67.10±10.89 years. Moreover, they treated 66 patients with UFH and 34 with enoxaparin. The mean duration of hospital stay in the UFH group was 4.36±2.3 and was 4.85±2.9 in the enoxaparin group (p=0.126). The mean direct medical cost per day was calculated as INR 435.05±50.002 for UFH and INR 926.03±81.462 for enoxaparin (p=0.166), while the direct medical cost considering the mean duration of use was INR 1897.50±1021.9 and INR 4547.79±2710.6, respectively, in both groups (p=0.000). The cost of laboratory monitoring was INR 677.27±218.94 with UFH and INR 308.82±51.45 with enoxaparin (p=0.000). The total cost, including laboratory monitoring, was INR 2574.77±1211.69 in the UFH group and INR 4856.62±2717.9 in the enoxaparin group.
Conclusion: Direct medical costs associated with UFH were lower than those of enoxaparin; hence, short-term treatment with UFH for AMI in hospitalized patients provided cost savings in a tertiary care hospital in South Kerala.
Downloads
References
1. Mensah GA, Fuster V, Murray CJ, Roth GA. Null, Mensah GA, et al. Glob burden cardiovasc dis risks. 1990-2022. J Am Coll Cardiol. 2023 Dec 19;82(25):2350-473.
2. Risk Factors for Coronary Artery Disease: Practice Essentials, Risk Factor Biomarkers, Conventional Risk Factors. Available from: https:// emedicine.medscape.com/article/164163-overview [Last accessed on 2025 Jun 27].
3. Tern PJ, Yeo KK, Tan JW, Chin CT, Tan RS, Yap J. Role of anticoagulation in non-ST-elevation myocardial infarction: A contemporary narrative review. Expert Rev Cardiovasc Ther. 2024 Jun 2;22(6):203-15. doi: 10.1080/14779072.2024.2354243, PMID 38739469
4. Bertoli ED, Barros ML, Pasqualotto E, Lima PL, Camerotte R, Nienkötter TF, et al. Enoxaparin versus unfractionated heparin in acute coronary syndrome without ST-segment elevation: Asystematic review and meta-analysis. Int J Cardiovasc Sci. 2025;38:e20240149.
5. Gouin-Thibault I, Mansour A, Hardy M, Guéret P, De Maistre E, Siguret V, et al. Management of therapeutic-intensity unfractionated heparin: A narrative review on critical points. TH Open. 2024 Oct 17;8(3):e297-307. doi: 10.1055/a-2359-0987, PMID 39420916
6. Xiang T, Cheng M. Enoxaparin-induced reactive thrombocytosis: A case report. Thromb J. 2021 May 26;19(1):34. doi: 10.1186/s12959- 021-00290-x, PMID 34039362
7. Imbalzano E, Orlando L, Dattilo G, Gigliotti De Fazio M, Camporese G, Russo V, et al. Update on the pharmacological actions of enoxaparin in nonsurgical patients. Medicina (Kaunas). 2024 Jan 15;60(1):156. doi: 10.3390/medicina60010156, PMID 38256416
8. Galli M, Andreotti F, D’Amario D, Vergallo R, Vescovo GM, Giraldi L, et al. Antithrombotic therapy in the early phase of non-ST-elevation acute coronary syndromes: A systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2020 Jan 1;6(1):43-56. doi: 10.1093/ ehjcvp/pvz031, PMID 31350546
9. Patel P, Varacallo MA. Low-Molecular-Weight Heparin (LMWH). In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2025. Available from: https://www.ncbi.nlm.nih.gov/books/nbk525957 [Last accessed on 2025 Jul 19].
10. Veeranki SP, Xiao Z, Levorsen A, Sinha M, Shah BR. Real-world comparative effectiveness and cost comparison of thromboprophylactic use of enoxaparin versus unfractionated heparin in 376,858 medically Ill hospitalized US patients. Am J Cardiovasc Drugs. 2021;21(4):443-52. doi: 10.1007/s40256-020-00456-4, PMID 33313988
11. Amin A, Kartashov A, Ngai W, Steele K, Rosenthal N. Effectiveness, safety, and costs of thromboprophylaxis with enoxaparin or unfractionated heparin in inpatients with obesity. Front Cardiovasc Med. 2023;10:1163684. doi: 10.3389/fcvm.2023.1163684, PMID 37396589
12. Tonin FS, Aznar-Lou I, Pontinha VM, Pontarolo R, Fernandez-Llimos F. Principles of pharmacoeconomic analysis: The case of pharmacist-led interventions. Pharm Pract (Granada). 2021;19(1):2302. doi: 10.18549/ PharmPract.2021.1.2302, PMID 33727994
13. Argenta C, Ferreira MA, Sander GB, Moreira LB. Short-term therapy with enoxaparin or unfractionated heparin for venous thromboembolism in hospitalized patients: Utilization study and cost-minimization analysis. Value Health. 2011 Jul;14(5) Suppl 1:S89-92. doi: 10.1016/j. jval.2011.05.017, PMID 21839908
14. Pawar DA, Kale A, Otari K. Pharmacoeconomics in healthcare: Optimizing costs and outcomes in pharmacotherapy. Int J Pharm Sci. 2024;2(9):606-14.
15. Tanjung R, Wardati Y, Yulianingsih Y, Widyawati IE, Mustarichie R, Saptarini NM. Cost-effectiveness analysis of treatment in gastroesophageal reflux disease inpatients in Bandung, Indonesia. Int J Appl Pharm. 2023 Dec 18:141-4. doi: 10.22159/ijap.2023.v15s2.26
16. Mehra A, Bhat NK, Sharma SK, Khajuria K. Drug prescribing pattern in patients of myocardial infarction in a tertiary care teaching hospital of North India. Int J Basic Clin Pharmacol. 2020;9(9):1357. doi: 10.18203/2319-2003.ijbcp20203523
17. Sidhu NS, Rangaiah SK, Ramesh D, Veerappa K, Manjunath CN. Clinical characteristics, management strategies, and in-hospital outcomes of acute coronary syndrome in a low socioeconomic status cohort: An observational study from Urban India. Clin Med Insights Cardiol. 2020 May 7;14:1179546820918897. doi: 10.1177/1179546820918897, PMID 32425627
18. Gupta MD, Girish MP, Kategari A, Batra V, Gupta P, Bansal A, et al. Epidemiological profile and management patterns of acute myocardial infarction in very young patients from a tertiary care center. Indian Heart J. 2020;72(1):32-9. doi: 10.1016/j.ihj.2020.03.003, PMID 32423558
19. Rezaianzadeh A, Dastoorpoor M, Sanaei M, Salehnasab C, Mohammadi MJ, Mousavizadeh A. Predictors of length of stay in the coronary care unit in patient with acute coronary syndrome based on data mining methods. Clin Epidemiol Glob Health. 2020 Jun;8(2):383-8. doi: 10.1016/j.cegh.2019.09.007
20. Chen P, Zhang M, Zhang Y, Su X, Chen J, Xu B, et al. Economic burden of myocardial infarction combined with dyslipidemia. Front Public Health. 2021 Feb 19;9:648172. doi: 10.3389/fpubh.2021.648172, PMID 33681139
Published
How to Cite
Issue
Section
Copyright (c) 2025 Liya Roslin Joseph
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
